EUVIMEDEUVIMED entdecken
Crossref

Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?

Przemysław Witek, Marta Mazur, Joanna Witek

OncoReview · 2017

DOI: 10.24292/01.or.211217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift OncoReview, 2017. Verfasst von Przemysław Witek und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cushing’s disease is a rare endocrine disorder caused by ACTH-secreting pituitary adenoma. The treatment of choice is a transsphenoidal surgery performed by an experienced neurosurgeon. However, in some patients adjuvant treatment is required due to ineffective surgery or disease recurrence. This article discusses new aspects of pharmacological treatment of ACTH-dependent hypercortisolism in light of a recent publication reporting the efficacy and safety of once a month pasireotide LAR injections in Cushing’s disease

Zitieren

APA

Witek, P., Mazur, M., & Witek, J. (2017). Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?. OncoReview. https://doi.org/10.24292/01.or.211217

Vancouver

Witek P, Mazur M, Witek J. Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?. OncoReview. 2017. doi:10.24292/01.or.211217

BibTeX
@article{Witek2017,
  author = {Witek, Przemysław and Mazur, Marta and Witek, Joanna},
  title = {Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?},
  journal = {OncoReview},
  year = {2017},
  doi = {10.24292/01.or.211217}
}
Kostenlos starten →